Corcept Therapeutics (CORT) CFO sells 40,000 shares and exercises options
Rhea-AI Filing Summary
Corcept Therapeutics Chief Financial Officer Atabak Mokari reported option exercises and share sales in the company’s common stock. On July 15, 2026, he exercised stock options for a total of 40,000 shares at exercise prices of $23.0600 and $19.2600 per share, then sold 40,000 shares in open-market transactions at weighted average prices between $86.7760 and $89.4282 per share, with actual sale prices ranging from $86.20 to $89.43. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, and the options exercised were fully exercisable.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 40,000 shares ($3,508,277)
Net Sell
8 txns
Insider
Mokari Atabak
Role
Chief Financial Officer
Sold
40,000 shs ($3.51M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 15,833 | $0.00 | -- |
| Exercise | Stock option (right to buy) | 24,167 | $0.00 | -- |
| Exercise | Common Stock | 15,833 | $19.26 | $305K |
| Exercise | Common Stock | 24,167 | $23.06 | $557K |
| Sale | Common Stock | 7,919 | $86.776 | $687K |
| Sale | Common Stock | 28,460 | $87.8863 | $2.50M |
| Sale | Common Stock | 3,520 | $88.3016 | $311K |
| Sale | Common Stock | 101 | $89.4282 | $9K |
Holdings After Transaction:
Stock option (right to buy) — 4,167 shares (Direct);
Common Stock — 31,963 shares (Direct)
Footnotes (1)
- Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Fully exercisable.
Key Figures
Shares sold: 40000 shares
Shares acquired via option exercise: 40000 shares
Option exercise price: $23.0600 per share
+3 more
6 metrics
Shares sold
40000 shares
Total common shares sold in open-market transactions on 2026-07-15
Shares acquired via option exercise
40000 shares
Total common shares received from stock option exercises on 2026-07-15
Option exercise price
$23.0600 per share
Exercise price for 24167 stock options converted into common stock
Option exercise price
$19.2600 per share
Exercise price for 15833 stock options converted into common stock
Sale price range
$86.20–$89.43 per share
Actual sale price range across reported sales, per weighted-average price footnotes
10b5-1 plan adoption date
December 12, 2025
Date the CFO adopted the Rule 10b5-1 trading plan covering these sales
Key Terms
10b5-1 plan, weighted average sale price, restricted stock awards, Stock option (right to buy)
4 terms
10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person..."
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold..."
restricted stock awards financial
"Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person..."
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
Stock option (right to buy) financial
"Security title reported as Stock option (right to buy) with underlying common shares"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transactions did Corcept Therapeutics (CORT) CFO Atabak Mokari report?
Atabak Mokari reported exercising stock options for 40,000 Corcept shares and selling 40,000 common shares on July 15, 2026. The activity combined option exercises at preset strike prices with open-market sales executed under a pre-arranged Rule 10b5-1 trading plan.
What stock options did the Corcept (CORT) CFO exercise?
He exercised options covering 24,167 shares at $23.0600 per share and 15,833 shares at $19.2600 per share, for a total of 40,000 shares. Footnotes state these stock options were fully exercisable at the time of the transactions.
Were Mokari’s Corcept (CORT) trades made under a Rule 10b5-1 plan?
Yes. A footnote explains the reported sales were made pursuant to a Rule 10b5-1 trading plan adopted by Atabak Mokari on December 12, 2025. The filing’s 10b5-1 checkbox is also marked, indicating plan-based transactions.
Do Mokari’s Corcept (CORT) holdings include unvested restricted stock awards?
Reported holdings include shares underlying unvested restricted stock awards: 200 shares from a September 2, 2025 grant, 178 from December 1, 2025, 397 from March 2, 2026, and 634 from June 1, 2026. Each award vests 100% on its one-year anniversary if conditions are met.